CHA Vaccine Institute

CHA Vaccine Institute, based in Seongnam, South Korea, focuses on the development and commercialization of innovative vaccines and immunotherapeutics to address critical health needs globally. Founded in 2000, CHA Vaccine Institute is dedicated to vaccine development, notably in hepatitis B and influenza. Led by CEO Jung-sun Yum, the company has participated in 7 deals and raised a total of KRW 43. 45 billion in its IPO on October 22, 2021.

CHA Vaccine Institute specializes in advanced vaccines and immunotherapeutics. Its offerings include a third-generation hepatitis B vaccine, an immunotherapeutic for chronic hepatitis B, a recombinant herpes zoster vaccine, and an enhanced quadrivalent influenza vaccine aimed at improving immunogenicity. The institute serves healthcare providers and pharmaceutical distributors, delivering products to North America, Europe, and parts of Asia. In 2024, CHA Vaccine Institute reported revenue of KRW 271,943.

7 mn, with an EBITDA loss of KRW 5,302,861. 6 mn for the same year, primarily generated through partnerships with healthcare organizations and B2B sales to pharmaceutical distributors. CHA Vaccine Institute aims to launch new vaccine products in the upcoming years. Following its IPO in October 2021, the company plans to utilize the raised funds to expand into additional markets in Asia and Europe by 2025.

This strategic initiative is designed to enhance its market presence and cater to the growing demand for effective vaccines globally.